Opthopin-LS Eye Drop contains Atropine 0.01% w/v, a muscarinic antagonist used primarily for ophthalmic purposes. Atropine acts by inhibiting the parasympathetic innervation of the eye, leading to pupil dilation (mydriasis) and paralysis of the ciliary muscle (cycloplegia). This low concentration formulation is indicated for diagnostic procedures requiring pupil dilation, such as fundus examination, and for the management of certain inflammatory conditions of the anterior segment of the eye, including anterior uveitis. The 0.01% strength minimizes systemic absorption and adverse effects while providing effective localized action. Opthopin-LS Eye Drop should be administered as directed by a healthcare professional, typically instilled into the conjunctival sac one to two times daily depending on the clinical indication. Caution is advised in patients with narrow-angle glaucoma, hypersensitivity to atropine or its derivatives, and in pediatric populations due to the risk of systemic anticholinergic effects. Common adverse reactions may include transient stinging, blurred vision, photophobia, and local irritation. Patients should avoid driving or operating machinery until the effects on vision have resolved. Proper storage and handling instructions should be followed to maintain sterility and efficacy.